Olaparib 100 mg, 150 mg Tablets at Best Price - Oddway
www.oddwayinternational.com/olaparib-tab...

#Jospin #Lionel #LFI #Lunes #Municipales #Matin #Socialiste #Campagne #Jean #Résultats #LFI #Jospin #SPD #Lionel #點 #이거 #AfD #Matin #Perdu #Faure #health #Medicine #Cancer #OvarianCancerDrug #Olaparib

New findings indicate that PAK1 inhibition enhances #Olaparib sensitivity in #OvarianCancer, paving the way for improved therapeutic outcomes. @mayoclinic.org #medsky

#OpenAccess: www.sciencedirect.com/science/arti...

The estimated long-term clinical effects of BRCA testing and olaparib treatment of early breast cancer in the US population: a population impact model Olaparib is approved for the treatment of germline BRCA mutant (gBRCAm) high-risk early breast cancer (eBC) following treatment with neoadjuvant or adjuvant chemotherapy. The potential long-term ou...

#BRCA testing & subsequent treatment with #olaparib results in ⬇️ recurrences in early BC & ⬆️ life expectancy vs no testing & no treatment, suggesting there is substantial clinical value in widespread testing for this population.

#bcsm #hereditarycancer #PARP #cancerresearch #medsky #womenshealth

Today at the #DGHO Annual Meeting 2025 #Cologne: #GBG presents exciting new research on combination therapy for #BRCA-mutated #breastcancer! Proud to share the #ELEMENT study #GBG114 — a randomized phase II trial exploring whether adding the oral #SERD #elacestrant to the #PARP inhibitor #olaparib.

A trial among #BRCA carriers comparing neoadjuvant #chemo with #olaparib vs. chemo alone found no improvement in pathologic response (64.1% vs. 69.8%) yet significant improvement in overall survival at 3 yrs (100% vs. 88.2%). Read the full article at: www.nature.com/articles/s41...

Positive phase 2 data of #olaparib in patients with advanced biliary tract cancer #BTC #CCA with aberrant #HRR mutations presented today at #ESMOGI25 @myesmo.bsky.social #ESMOAmbassadors

Tumor-Agnostic Trial Finds PARP Inhibitor and Anti-PD-L1 Combo Beneficial Across Cancer Types Tumors that harbor mutations or deficiencies in DNA repair pathways may respond to the combination of a PARP inhibitor and immune checkpoint inhibitor, with tumors positive for BRCA1/2 mutations espec...

Tumour-agnostic trial shows promise: Combining #olaparib + #pembrolizumab proves effective across multiple cancer types with #HRR or #HRD mutations in the KEYLYNK-007 study. A big step in oncology. #CancerResearch #PARPinhibitor #Immunotherapy #TCSC

www.oncologynewscentral.com/oncology/tum...

Comparing #durvalumab, #olaparib, and #cediranib, or chemotherapy in platinum-resistant #ovariancancer: the @nrgonc.bsky.social GY023 trial

url:aacrjournals.org/clincancerres/article-ab...

#gyncsm

Drug Trials Saved Lenny, and Will Help Thousands More | Duke Today

#ClinicalTrial Saved #BRCA+ male with #prostatecancer & Will Help Thousands More @dukepress.bsky.social

#hereditarycancer #genetics #menshealth #olaparib #cancerresearch #oncsky

Exploratory Post Hoc Analysis of DUO-E Reveals Olaparib’s Benefit in Endometrial Cancer Subsets The phase III DUO-E study evaluated the addition of the monoclonal antibody durvalumab to chemotherapy, and the benefit of maintenance durvalumab, with and without the PARP inhibitor olaparib, in adva...

Adding #Olaparib to chemo + #Durvalumab significantly boosts progression-free survival in the pMMR subgroup. Key findings: benefit across biomarkers & ctDNA detection. What’s next for personalized treatment?

🔗 ascopost.com/issues/march...

#Oncology #CancerResearch

Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status - British Journal of Cancer British Journal of Cancer - Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status

Overall survival with maintenance #olaparib in platinum-sensitive relapsed #ovariancancer by somatic or germline #BRCA and homologous recombination repair mutation status. @nature.com

#gyncsm #hereditarycancer #womenshealth #genetics #cancerresearch #PARP

Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial - PubMed Olaparib does not have sufficient single-agent activity to warrant further development in IDH-mutant CCA. However, a subgroup of patients demonstrated CB, and exploratory analysis revealed this subgro...

A study led by Dr. Patricia LoRusso shows #Olaparib demonstrated clinical benefit in a subgroup of pts with IDH-mutant cholangiocarcinoma #CCA, + exploratory analysis revealed this subgroup to be enriched for lower baseline 2-HG levels. pubmed.ncbi.nlm.nih.gov/39917990/
@ranjitbindra.bsky.social

PhD student Tao Xie from our group presenting her research at #ANZGOG2025ASM this week on discovering new ways to address acquired resistance to #PARPinhibitors in #OvarianCancer. A bustling poster session! #High-GradeSerousOvarianCancer #DrugResistance #olaparib #niraparib 🧪

Real‐World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1‐2 Pathogenic Variants In a real-world population of Italian patients with advanced pancreatic cancer carrying germline BRCA pathogenic variants, exposure to olaparib resulted in significantly longer overall survival. Howe...

Real-World Impact of #Olaparib Exposure in Advanced #PancreaticCancer Patients Harboring Germline #BRCA Pathogenic Variants: This #PARP therapy may significantly improve survival per Italian study.

#pancsm #pancchat #oncsky #hereditarycancer #precisionmedicine #genetics #openaccess

NICE recommends olaparib for advanced breast cancer in final draft guidance The National Institute for Health and Care Excellence (NICE) has recommended olaparib (Lynparza; AstraZeneca) for treatment of HER2-negative locally advanced or metastatic breast cancer in adults…

Final draft guidance from #NICE has recommended olaparib for advanced breast cancer

#olaparib #lynparza #AstraZeneca

NICE recommends olaparib for BRCA-mutated breast cancer treatment - PharmaTimes Groundbreaking approval provides new hope for patients in England and Wales

#precisionmedicine #PARPinhibitor #breastcancer #NICErecommended #olaparib #Lynparza #AstraZeneca #AstraZenecaUK #AstraZenecaOncology #genetictesting #OlympiADclinicaltrail #OlympiADphase3trial #BRCAmutations #TestingforBRCAmutations #NationalGenomicTestDirectory
pharmatimes.com/news/nice-re...

The ICR has played a crucial role in the development of the targeted drug #Olaparib.

Professor Kristian Helin, (@helink.bsky.social) - Chief Executive of the ICR, said: "I’m proud of the decades of research at the ICR that have underpinned this achievement."

OlympiA Trial: Long-Term Benefits of Olaparib Confirmed in High-Risk Subgroup of Breast Cancer For women with high-risk, BRCA-positive breast cancer, 1 year of adjuvant treatment with the PARP inhibitor olaparib following primary treatment continued to improve overall survival compared with pla...

OlympiA Trial: Long-Term Benefits of #Olaparib Confirmed in High-Risk Subgroup of #BreastCancer
@danafarber.bsky.social @ascopost.bsky.social

#BRCA #hereditarycancer #clinicaltrial #bcsm #cancerresearch #womenshealth #SABCS

#Olaparib (Lynparza®)
#BRCA #cancer

5 papers about Lung Cancer suggested by Stephen Liu - OncoDaily 5 papers about Lung Cancer suggested by Stephen Liu / atezolizumab, cancer, carboplatin, Catherine B. Meador, Daniele Tavernari, Eisaku Miyauchi, etoposide,

5 papers about Lung Cancer suggested by Stephen Liu
@stephenvliu.bsky.social

oncodaily.com/science/step...

#Atezolizumab #Cancer #Carboplatin #Etoposide #Medicine #Health #LungCancer #LCSM #Nivolumab #NSCLC #Olaparib #OncoDaily #Oncology #SCLC #Temozolomide

Our research impact: PARP inhibitors To mark our outstanding success in REF2021, Alison Halliday spoke to several of our researchers here at the ICR who were instrumental in the development of PARP inhibitors, a type of targeted drug tha...

In this feature we explored our research into #PARPinhibitors like #olaparib, which are now used to treat some forms of #BreastCancer, #OvarianCancer and #ProstateCancer.

It's just one example of an ICR research programme that's changed the lives of cancer patients.

www.icr.ac.uk/news-feature...

Updated 6yr data #OlympiA by #DrJudyGarber ➡️ continued benefit 12 mon adjuvant #olaparib for gBRCA mut, stage 2/3 or residual cancer post-NACT. 1) further ⬆️ iDFS 9.4% in both #tnbc #ER+ 2) persistent ⬆️ DDFS 7.8%; 3) ⬆️ OS 4.4% 5) ⬇️ CNS Mets, ⬇️ new cancers 6) ↔️ MDS/AML @sabcs.bsky.social #SABCS24

Dr. Judy Garber shared the OlympiA Phase 3 trial results in today's #SABCS24 General Session. #olaparib #BRCA1 #BRCA2 #BreastCancer

Institute of Cancer Research

📰 NEWS: Latest findings from the OlympiA clinical trial show prolonged benefit of #olaparib against early-stage #BreastCancer with inherited BRCA mutations.

The research, involving ICR scientists, is presented today at @sabcs.bsky.social. #SABCS24

Read more ⬇️

www.icr.ac.uk/news-archive...